The Indian Journal of Pediatrics

, Volume 71, Issue 9, pp 825–835 | Cite as

Optimum management of pediatric patients with fever and neutropenia

  • Aditya H. Gaur
  • Patricia M. Flynn
  • Jerry L. Shenepu
Symposium on Protocols for Managing Severe Infections-I


Fever with neutropenia is a common clinical problem in patients receiving cancer treatment. Prevention and optimum management of infectious complications is critical to the overall success of cancer therapy. This article provides an overview of the current status of this evolving subject. While the basic principles of rapid institution of broad spectrum antibiotics, early intervention with empiric antifungal therapy and continuation of antimicrobials during period of risk are unlikely to change, there is increasing interest in titrating this aggressive approach based on the projected risk of the development of a serious invasive infection. Oral antibiotic therapy and outpatient management are currently being studied in pediatric oncology patients, but even when successful these alternatives to the traditional “in hospital, parenteral antibiotic therapy” approach are unlikely to be applicable in all patient populations and clinical settings. While there is no replacement for clinical acumen and careful monitoring, judicious use of diagnostic resources such as blood cultures and imaging studies is a key component of optimum care. Selection of empiric antibiotics based on ongoing monitoring of antimicrobial susceptibility patterns is emphasized.

Key words

Neutropenia Febrile neutropenia Cancer Pediatric 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.Ann Intern Med 1966; 64(2): 328–340.PubMedGoogle Scholar
  2. 2.
    Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia.N Engl J Med 1971; 284(19): 1061–1065.PubMedCrossRefGoogle Scholar
  3. 3.
    Pizzo PA, Robichaud KJ, Gill FAet al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer.Am J Med 1979; 67(2): 194–200.PubMedCrossRefGoogle Scholar
  4. 4.
    Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia.Am JMed 1982; 72(1): 101–111.Google Scholar
  5. 5.
    Paganini HR, Sarkis CM, De Martino MGet al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer.Cancer 2000; 88(12): 2848–2852.PubMedCrossRefGoogle Scholar
  6. 6.
    Shenep JL, Flynn PM, Baker DKet al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer.Clin Infect Dis 2001; 32(1): 36–43.PubMedCrossRefGoogle Scholar
  7. 7.
    Mullen CA, Petropoulos D, Roberts WMet al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients.Cancer 1999; 86(1): 126–134.PubMedCrossRefGoogle Scholar
  8. 8.
    Petrilli AS, Dantas LS, Campos MCet al. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial.Med Pediatr Oncol 2000; 34(2): 87–91.PubMedCrossRefGoogle Scholar
  9. 9.
    Paganini H, Rodriguez-Brieshcke T, Zubizarreta Pet al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia.Cancer 2001; 91(8): 1563–1567.PubMedCrossRefGoogle Scholar
  10. 10.
    Paganini H, Gomez S, Ruvinsky Set al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina.Cancer 2003; 97(7): 1775–1780.PubMedCrossRefGoogle Scholar
  11. 11.
    Indian Society of Medical & Pediatric Oncology. Indian Guidelines-Febrile Neutropenia. 2002.Google Scholar
  12. 12.
    Uma A, Mehta A, Ayyagari Aet al. Prevalance of a-lactamase producing strains among clinical isolates obtained from hospital in-patients across India and comparision of antibacterial susceptibility using disc diffusion method. Hospital Today 2004 IX(1).Google Scholar
  13. 13.
    Mehndiratta PL, Vidhani S, Mathur MD. A study on Staphylococcus aureus strains submitted to a reference laboratory.Indian JMed Res 2001; 114: 90–94.Google Scholar
  14. 14.
    Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India. Invasive Bacterial Infection Surveillance (IBIS) Group, International Clinical Epidemiology Network (INCLEN).Lancet 1999; 353(9160): 1216–1221.CrossRefGoogle Scholar
  15. 15.
    Hughes WT, Armstrong D, Bodey GPet al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.Clin Infect Dis 2002; 34(6): 730–751.PubMedCrossRefGoogle Scholar
  16. 16.
    Gaur AH, Giannini MA, Flynn PMet al. Optimizing blood culture practices in pediatric immunocompromised patients: evaluation of media types and blood culture volume.Pediatr Infect Dis J 2003; 22(6): 545–552.PubMedCrossRefGoogle Scholar
  17. 17.
    Gaur AH, Flynn PM, Giannini MAet al. Difference in time to detection: a simple method to differentiate catheter-related from non-catheter-related bloodstream infection in immunocompromised pediatric patients.Clin Infect Dis 2003; 37(4): 469–475.PubMedCrossRefGoogle Scholar
  18. 18.
    Klastersky J, Paesmans M, Rubenstein EBet al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.J Clin Oncol 2000; 18(16): 3038–3051.PubMedGoogle Scholar
  19. 19.
    Santolaya ME, Alvarez AM, Aviles CLet al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia.Clin Infect Dis 2002; 35(6): 678–683.PubMedCrossRefGoogle Scholar
  20. 20.
    Klaassen RJ, Goodman TR, Pham B, Doyle JJ. Low-risk prediction rule for pediatric oncology patients presenting with fever and neutropenia.J Clin Oncol 2000; 18(5): 1012–1019.PubMedGoogle Scholar
  21. 21.
    Ammann RA, Hirt A, Luthy AR, Aebi C. Predicting bacteremia in children with fever and chemotherapy-induced neutropenia.Pediatr Infect Dis J 2004; 23(1): 61–67.PubMedCrossRefGoogle Scholar
  22. 22.
    Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials.BMJ 2004; 328(7441): 668.PubMedCrossRefGoogle Scholar
  23. 23.
    Del Favero A, Menichetti F, Martino Pet al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia.Clin Infect Dis 2001; 33(8): 1295–301.PubMedCrossRefGoogle Scholar
  24. 24.
    Gorschluter M, Hahn C, Fixson Aet al. Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison.Support Care Cancer 2003; 11(6): 362–370.PubMedGoogle Scholar
  25. 25.
    Winston DJ, Bartoni K, Bruckner DAet al. Randomized comparison of sulbactamJcefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients.Clin Infect Dis 1998; 26(3): 576–583.PubMedGoogle Scholar
  26. 26.
    Jones RN, Rhomberg PR, Varnam DJ, Mathai D. A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic Salmonella spp.: initial studies for the MYSTIC programme in India.Int J Antimicrob Agents 2002; 20(6): 426–431.PubMedCrossRefGoogle Scholar
  27. 27.
    Cometta A, Kern WV, De Bock Ret al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy.Clin Infect Dis 2003; 37(3): 382–389.PubMedCrossRefGoogle Scholar
  28. 28.
    Santolaya ME, Villarroel M, Avendano LF, Cofre J. Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study.Clin Infect Dis 1997; 25(1): 92–97.PubMedGoogle Scholar
  29. 29.
    Clark OA, Lyman G, Castro AAet al. Colony stimulating factors for chemotherapy induced febrile neutropenia.Cochrane Database Syst Rev 2003; (3): CD003039.Google Scholar
  30. 30.
    Bow EJ, Laverdiere M, Lussier Net al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.Cancer 2002; 94(12): 3230–3246.PubMedCrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2004

Authors and Affiliations

  • Aditya H. Gaur
    • 1
  • Patricia M. Flynn
    • 1
    • 2
    • 3
  • Jerry L. Shenepu
    • 1
    • 2
  1. 1.Department of Infectious DiseasesSt. Jude Children’s Research HospitalMemphisUSA
  2. 2.Department of PediatricsUniversity of Tennessee Health Science CenterMemphisUSA
  3. 3.Department of Preventive MedicineUniversity of Tennessee Health Science CenterMemphisUSA

Personalised recommendations